In 2025, the pharmaceutical industry found itself at a pivotal juncture driven by intense political and regulatory pressure. At the center has been the Trump Administration's push for Most Favored Nation (MFN) pricing – a policy designed to align U.S. drug prices with the lowest prices paid in comparable developed countries. Through executive actions and high-profile agreements with major manufacturers, the administration has effectively signaled that MFN pricing is not optional, linking tariff exemptions and regulatory benefits such as priority review vouchers to whether manufacturers agree to lower U.S. drug prices.

For many manufacturers, this pressure has accelerated a trend already underway: experimentation with direct-to-consumer (DTC) pricing and sales models. Historically, pharmaceutical distribution has relied on insurers, pharmacy benefit managers, and traditional retail channels. But when faced with the need to deliver lower prices and broader access, some companies have launched their own DTC channels or partnered with telehealth platforms to sell medications directly to patients, including at discounted cash prices outside of insurance coverage.

These DTC initiatives can offer advantages. Patients may see simplified pricing and potentially lower out-of-pocket costs, and manufacturers can bypass traditional intermediaries, gain more flexibility over prices, and blunt calls for full MFN adoption. At the same time, however, the legal and regulatory spotlight on these models has intensified.

In July 2025, an investigation by four U.S. senators raised questions about emerging DTC telehealth platforms tied to major manufacturers. The investigation cited concerns about potential conflicts of interest, high prescription rates among routed patients, data sharing, and limited clinical evaluation in virtual encounters, and further suggested that such arrangements could violate the federal Anti-Kickback Statute. In September 2025, the U.S. Food and Drug Administration (FDA) executed a "crackdown" on DTC drug promotion by sending warning and cease-and-desist letters to manufacturers over what it said were ads that misleadingly emphasized benefits, downplayed risks, or relied on oversimplified digital messaging. FDA's actions signal that DTC platforms remain subject to traditional promotional rules, regardless of format or distribution channel.

For industry leaders, 2026 will demand careful calibration. Pursuing DTC models may be a strategic necessity under MFN pricing pressure, but it also invites legal and regulatory scrutiny. Manufacturers structuring telehealth collaborations, for example, should clearly insulate clinical decision-making from marketing activities and avoid incentives that could be perceived as influencing prescribing behavior. They should also review DTC messaging through a heightened promotional-compliance lens, with particular attention to fair balance, risk disclosure, and substantiation of affordability and access claims across digital platforms. Manufacturers that strike these balances will be better positioned to expand access, respond to pricing pressure, and withstand growing scrutiny from regulators in the year ahead.